Nasal submucosal administration of antigen-presenting cells induces effective immunological responses in cancer immunotherapy
Migration and immunological reaction after the administration of αGalCer-pulsed antigen-presenting cells into the submucosa of patients with head and neck cancer
Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.
Phase I study of alpha-galactosylceramide-pulsed antigen presenting cells administration to the nasal submucosa in unresectable or recurrent head and neck cancer
Meet Funakoshi Company
Please visit our booth at one of these 2012 meetings:
AACR Booth# 333 April 1-4, 2012 NIH Spring Festival Booth# 903 April 25-26, 2012
